Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: A case report

Journal of Medical Case Reports

Volumn 8, Issue 1, 2014, Pages

  Ishizuna, Kazuo ^a   Ninomiya, Jun ^a,b   Ogawa, Toshihisa ^a   Tsuji, Eiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Ninomiya Hospital   (Japan)

Author keywords

Breast cancer; Hepatotoxicity; Trastuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; GAMMA UROGASTRONE; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LYMPH NODE DISSECTION; LYMPHOCYTE TRANSFORMATION TEST; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG-INDUCED LIVER INJURY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MIDDLE AGED; TRASTUZUMAB;

EID: 84924056733     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-8-417     Document Type: Article

References (11)

1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353 (16):1659-1672.
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726.
4. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17(9):2639-2648.
5. Masood S, Bui MM: Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000, 30:259-265.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
7. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
9. Muñoz A, Carrera S, Ferreiro J, de Lobera AR, Mañé JM, López-Vivanco G: Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer. Ann Oncol 2007, 18(12):2045-2046.
10. Srinivasan S, Parsa V, Liu CY, Fontana JA: Trastuzumab-induced hepatotoxicity. Ann Pharmacother 2008, 42(10):1497-1501.
11. Vucicevic D, Carey EJ, Karlin NJ: Trastuzumab-induced hepatotoxicity: a case report. Breast Care (Basel) 2013, 8(2):146-148.